LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

    Watanabe, Tatsuro / Yamamoto, Yuta / Kurahashi, Yuki / Kawasoe, Kazunori / Kidoguchi, Keisuke / Ureshino, Hiroshi / Kamachi, Kazuharu / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Nakamura, Hideaki / Okada, Seiji / Sueoka, Eisaburo / Kimura, Shinya

    Blood advances

    2024  Volume 8, Issue 6, Page(s) 1345–1358

    Abstract: Abstract: Adult T-cell leukemia/lymphoma (ATL) is triggered by infection with human T-cell lymphotropic virus-1 (HTLV-1). Here, we describe the reprogramming of pyrimidine biosynthesis in both normal T cells and ATL cells through regulation of uridine- ... ...

    Abstract Abstract: Adult T-cell leukemia/lymphoma (ATL) is triggered by infection with human T-cell lymphotropic virus-1 (HTLV-1). Here, we describe the reprogramming of pyrimidine biosynthesis in both normal T cells and ATL cells through regulation of uridine-cytidine kinase 2 (UCK2), which supports vigorous proliferation. UCK2 catalyzes the monophosphorylation of cytidine/uridine and their analogues during pyrimidine biosynthesis and drug metabolism. We found that UCK2 was overexpressed aberrantly in HTLV-1-infected T cells but not in normal T cells. T-cell activation via T-cell receptor (TCR) signaling induced expression of UCK2 in normal T cells. Somatic alterations and epigenetic modifications in ATL cells activate TCR signaling. Therefore, we believe that expression of UCK2 in HTLV-1-infected cells is induced by dysregulated TCR signaling. Recently, we established azacitidine-resistant (AZA-R) cells showing absent expression of UCK2. AZA-R cells proliferated normally in vitro, whereas UCK2 knockdown inhibited ATL cell growth. Although uridine and cytidine accumulated in AZA-R cells, possibly because of dysfunction of pyrimidine salvage biosynthesis induced by loss of UCK2 expression, the amount of UTP and CTP was almost the same as in parental cells. Furthermore, AZA-R cells were more susceptible to an inhibitor of dihydroorotic acid dehydrogenase, which performs the rate-limiting enzyme of de novo pyrimidine nucleotide biosynthesis, and more resistant to dipyridamole, an inhibitor of pyrimidine salvage biosynthesis, suggesting that AZA-R cells adapt to UCK2 loss by increasing de novo pyrimidine nucleotide biosynthesis. Taken together, the data suggest that fine-tuning pyrimidine biosynthesis supports vigorous cell proliferation of both normal T cells and ATL cells.
    MeSH term(s) Adult ; Humans ; Pyrimidines ; Uridine/metabolism ; Cell Proliferation ; Cytidine ; Human T-lymphotropic virus 1 ; Pyrimidine Nucleotides ; Receptors, Antigen, T-Cell ; T-Lymphocytes/metabolism
    Chemical Substances Pyrimidines ; Uridine (WHI7HQ7H85) ; Cytidine (5CSZ8459RP) ; Pyrimidine Nucleotides ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2024-01-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023011131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Acute myeloid leukaemia presenting with ecthyma gangrenosum as the first manifestation: A case report.

    Hadano, Yoshiro / Yoshida-Sakai, Nao / Imamura, Yutaka / Inoue, Tomohiro / Koga, Hitoshi

    Medicine

    2021  Volume 100, Issue 18, Page(s) e25867

    Abstract: Rationale: Ecthyma gangrenosum (EG) is an uncommon cutaneous infection usually associated with Pseudomonas aeruginosa bacteremia in immunocompromised patients, particularly those with underlying malignant diseases. Despite its rarity, especially in ... ...

    Abstract Rationale: Ecthyma gangrenosum (EG) is an uncommon cutaneous infection usually associated with Pseudomonas aeruginosa bacteremia in immunocompromised patients, particularly those with underlying malignant diseases. Despite its rarity, especially in immunocompetent or nondiagnosed immunodeficiency patients, EG can present as the first manifestation of an underlying immunosuppression.
    Patient concerns: A 42-year-old Japanese man was admitted to our hospital with a 3-day history of a painless red macule on his right forearm and fever.
    Diagnoses: Blood culture on admission revealed the presence of Pseudomonas aeruginosa, whereas pus culture of the skin lesion showed Pseudomonas aeruginosa and methicillin-susceptible Staphylococcus aureus positivity.
    Interventions: Additional bone marrow aspirate examination and immunophenotyping were performed to confirm the diagnosis of acute promyelocytic leukaemia with PML-retinoic acid alpha receptor.
    Outcomes: The patient was successfully treated with a 14-day course of antibiotics, and no evidence of relapse was noted. The patient achieved complete remission after treatment for acute promyelocytic leukaemia.
    Lessons: It should be kept in mind that EG is an important cutaneous infection that is typically associated with P aeruginosa bacteremia and the presence of underlying immunodeficiency, such as acute leukaemia.
    MeSH term(s) Adult ; Anti-Bacterial Agents/therapeutic use ; Bone Marrow/pathology ; Coinfection/diagnosis ; Coinfection/drug therapy ; Coinfection/immunology ; Coinfection/microbiology ; Drug Therapy, Combination ; Forearm ; Humans ; Immunocompromised Host ; Leukemia, Promyelocytic, Acute/complications ; Leukemia, Promyelocytic, Acute/diagnosis ; Leukemia, Promyelocytic, Acute/immunology ; Male ; Pseudomonas Infections/diagnosis ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/immunology ; Pseudomonas Infections/microbiology ; Pseudomonas aeruginosa/immunology ; Pseudomonas aeruginosa/isolation & purification ; Pyoderma Gangrenosum/diagnosis ; Pyoderma Gangrenosum/drug therapy ; Pyoderma Gangrenosum/immunology ; Pyoderma Gangrenosum/microbiology ; Skin/microbiology ; Staphylococcal Skin Infections/diagnosis ; Staphylococcal Skin Infections/drug therapy ; Staphylococcal Skin Infections/immunology ; Staphylococcal Skin Infections/microbiology ; Staphylococcus aureus/immunology ; Staphylococcus aureus/isolation & purification ; Treatment Outcome
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2021-04-26
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 80184-7
    ISSN 1536-5964 ; 0025-7974
    ISSN (online) 1536-5964
    ISSN 0025-7974
    DOI 10.1097/MD.0000000000025867
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.

    Kamachi, Kazuharu / Ureshino, Hiroshi / Watanabe, Tatsuro / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Kawasoe, Kazunori / Hoshiko, Toshimi / Yamamoto, Yuta / Kurahashi, Yuki / Kimura, Shinya

    Cancer research communications

    2023  Volume 3, Issue 2, Page(s) 297–308

    Abstract: The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2-selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high ... ...

    Abstract The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2-selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high response rates, and potentially durable remission; however, because of low oral bioavailability, these conventional HMAs must be administered intravenously or subcutaneously. A combination of oral HMAs and Ven would provide a therapeutic advantage over parenteral administration of drugs and improve quality of life by reducing the number of hospital visits. Previously, we showed the promising oral bioavailability and antileukemia effects of a new HMA, OR2100 (OR21). Here, we investigated the efficacy and underlying mechanism of OR21 when used in combination with Ven to treat AML. OR21/Ven showed synergistic antileukemia effects
    Significance: The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects
    MeSH term(s) Humans ; Animals ; Mice ; Aged ; Quality of Life ; Azacitidine/pharmacology ; Antineoplastic Agents/pharmacology ; Leukemia, Myeloid, Acute/drug therapy
    Chemical Substances venetoclax (N54AIC43PW) ; Azacitidine (M801H13NRU) ; Antineoplastic Agents
    Language English
    Publishing date 2023-02-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2767-9764
    ISSN (online) 2767-9764
    DOI 10.1158/2767-9764.CRC-22-0259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

    Kawasoe, Kazunori / Watanabe, Tatsuro / Yoshida-Sakai, Nao / Yamamoto, Yuta / Kurahashi, Yuki / Kidoguchi, Keisuke / Ureshino, Hiroshi / Kamachi, Kazuharu / Fukuda-Kurahashi, Yuki / Kimura, Shinya

    Cancers

    2023  Volume 15, Issue 20

    Abstract: The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in ... ...

    Abstract The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in non-small cell lung carcinoma (NSCLC). Since
    Language English
    Publishing date 2023-10-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15205089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.

    Yoshida-Sakai, Nao / Watanabe, Tatsuro / Yamamoto, Yuta / Ureshino, Hiroshi / Kamachi, Kazuharu / Kurahashi, Yuki / Fukuda-Kurahashi, Yuki / Kimura, Shinya

    International journal of cancer

    2021  Volume 150, Issue 7, Page(s) 1184–1197

    Abstract: Adult T-cell leukemia-lymphoma (ATL) is an aggressive neoplasm derived from T-cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Recently, we reported that regional DNA hypermethylation in HTLV-1-infected T-cells reflects the disease status ...

    Abstract Adult T-cell leukemia-lymphoma (ATL) is an aggressive neoplasm derived from T-cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Recently, we reported that regional DNA hypermethylation in HTLV-1-infected T-cells reflects the disease status of ATL and the anti-ATL effects of DNA demethylating agents, including azacitidine (AZA), decitabine (DAC) and a new DAC prodrug, OR-2100 (OR21), which we developed. Here, to better understand the mechanisms underlying drug resistance, we generated AZA-, DAC- and OR21-resistant (AZA-R, DAC-R and OR21-R, respectively) cells from the ATL cell line TL-Om1 and the HTLV-1-infected cell line MT-2 via long-term drug exposure. The efficacy of OR21 was almost the same as that of DAC, indicating that the pharmacodynamics of OR21 were due to release of DAC from OR21. Resistant cells did not show cellular responses observed in parental cells induced by treatment with drugs, including growth suppression, depletion of DNA methyltransferase DNMT1 and DNA hypomethylation. We also found that reduced expression of deoxycytidine kinase (DCK) correlated with lower susceptibility to DAC/OR21 and that reduced expression of uridine cytidine kinase2 (UCK2) correlated with reduced susceptibility to AZA. DCK and UCK2 catalyze phosphorylation of DAC and AZA, respectively; reconstitution of expression reversed the resistant phenotypes. A large homozygous deletion in DCK and a homozygous splice donor site mutation in UCK2 were identified in DAC-R TL-Om1 and AZA-R TL-Om1, respectively. Both genomic mutations might lead to loss of protein expression. Thus, inactivation of UCK2 and DCK might be a putative cause of phenotypes that are resistant to AZA and DAC/OR21, respectively.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Azacitidine/therapeutic use ; Cell Line, Tumor ; DNA Methylation/drug effects ; Decitabine/therapeutic use ; Deoxycytidine Kinase/physiology ; Drug Resistance, Neoplasm ; Humans ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Leukemia-Lymphoma, Adult T-Cell/metabolism ; Pyridines/therapeutic use ; Pyrimidines/metabolism ; Uridine Kinase/physiology
    Chemical Substances Antineoplastic Agents ; OR-2100 ; Pyridines ; Pyrimidines ; Decitabine (776B62CQ27) ; UCK2 protein, human (EC 2.7.1.48) ; Uridine Kinase (EC 2.7.1.48) ; Deoxycytidine Kinase (EC 2.7.1.74) ; pyrimidine (K8CXK5Q32L) ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2021-12-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218257-9
    ISSN 1097-0215 ; 0020-7136
    ISSN (online) 1097-0215
    ISSN 0020-7136
    DOI 10.1002/ijc.33901
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.

    Kurahashi, Yuki / Watanabe, Tatsuro / Yamamoto, Yuta / Ureshino, Hiroshi / Kamachi, Kazuharu / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Yamashita, Satoshi / Hattori, Naoko / Nakamura, Hideaki / Kawaguchi, Atsushi / Ushijima, Toshikazu / Sueoka, Eisaburo / Kimura, Shinya

    Blood advances

    2022  Volume 7, Issue 8, Page(s) 1545–1559

    Abstract: Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T cells caused by human T-cell lymphotropic virus type 1 (HTLV-1)-induced T-cell transformation. After infection with HTLV-1, it takes several decades for HTLV-1 carriers to develop ATL. ...

    Abstract Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T cells caused by human T-cell lymphotropic virus type 1 (HTLV-1)-induced T-cell transformation. After infection with HTLV-1, it takes several decades for HTLV-1 carriers to develop ATL. The prognosis of ATL remains poor despite several new agents being approved in the last few years. Recently, it has been noted that epigenetic abnormalities, both DNA methylation and trimethylation at histone H3Lys27 (H3K27me3), contribute to ATL leukemogenesis. Here, we investigated the effect of combination treatment with DNA demethylating agents (azacitidine [AZA], decitabine (DAC), and OR-2100 (OR21), which is a silylated derivative of DAC) and inhibitors of enhancer of zeste homolog 2 (EZH2) (EPZ-6438 and DS-3201b), which catalyze trimethylation of H3K27, in ATL. The combination of DAC and OR21 but not AZA with EZH inhibitors exhibited synergistic anti-ATL effects in vitro and in vivo, concomitant with DNA demethylation and reduction of H3K27me3. The combination induced gene expression reprogramming. Dual-specificity phosphatase 5 (DUSP5), an extracellular signal-regulated kinase (ERK)-specific phosphatase, was identified as a key molecule that mediated the inhibitory effect of combination treatment by inactivating the ERK signaling pathway. DUSP5 was downregulated by DNA methylation and H3K27me3 accumulation in the promoter region in HTLV-1-infected cells from patients with ATL during ATL leukemogenesis. The present results demonstrate that dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth by restoring DUSP5, and that dual targeting of aberrant DNA and histone methylation is a feasible therapeutic approach for ATL.
    MeSH term(s) Adult ; Humans ; Histones/metabolism ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Leukemia-Lymphoma, Adult T-Cell/genetics ; Human T-lymphotropic virus 1/genetics ; Neoplasms/genetics ; DNA Methylation ; Azacitidine/pharmacology ; DNA/metabolism
    Chemical Substances Histones ; Azacitidine (M801H13NRU) ; DNA (9007-49-2)
    Language English
    Publishing date 2022-12-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022008362
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Coexistence of gastric and pulmonary MALT lymphoma and a clonally related, disseminated large B cell lymphoma with conspicuous angiotropism.

    Yoshida-Sakai, Nao / Oe, Kensuke / Kimura, Yoshizo / Ureshino, Hiroshi / Nomiyama, Keita / Hashiguchi, Michitoshi / Jojima, Hiroto / Imamura, Yutaka / Ohshima, Koichi / Okamura, Takashi

    Annals of hematology

    2022  Volume 101, Issue 6, Page(s) 1383–1385

    MeSH term(s) Helicobacter Infections/complications ; Helicobacter pylori ; Humans ; Lymphoma, B-Cell, Marginal Zone/complications ; Lymphoma, B-Cell, Marginal Zone/pathology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Lymphoma, Non-Hodgkin ; Stomach Neoplasms/complications ; Stomach Neoplasms/pathology
    Language English
    Publishing date 2022-02-23
    Publishing country Germany
    Document type Letter
    ZDB-ID 1064950-5
    ISSN 1432-0584 ; 0939-5555 ; 0945-8077
    ISSN (online) 1432-0584
    ISSN 0939-5555 ; 0945-8077
    DOI 10.1007/s00277-022-04752-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.

    Ureshino, Hiroshi / Kurahashi, Yuki / Watanabe, Tatsuro / Yamashita, Satoshi / Kamachi, Kazuharu / Yamamoto, Yuta / Fukuda-Kurahashi, Yuki / Yoshida-Sakai, Nao / Hattori, Naoko / Hayashi, Yoshihiro / Kawaguchi, Atsushi / Tohyama, Kaoru / Okada, Seiji / Harada, Hironori / Ushijima, Toshikazu / Kimura, Shinya

    Molecular cancer therapeutics

    2021  Volume 20, Issue 8, Page(s) 1412–1421

    Abstract: DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or ... ...

    Abstract DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or subcutaneously. Recently, two orally bioavailable DNA methyltransferase inhibitors, CC-486 and ASTX727, were approved. In previous work, we developed 5-O-trialkylsilylated decitabines that resist degradation by CDA. However, the effects of silylation of a deoxynucleotide analog and enzymatic cleavage of silylation have not been fully elucidated. Enteric administration of OR21 in a cynomolgus monkey model led to high plasma concentrations and hypomethylation, and in a mouse model, oral administration of enteric-coated OR21 led to high plasma concentrations. The drug became biologically active after release of decitabine (DAC) from OR21 following removal of the 5'-O-trisilylate substituent. Toxicities were tolerable and lower than those of DAC. Transcriptome and methylome analysis of MDS and AML cell lines revealed that OR21 increased expression of genes associated with tumor suppression, cell differentiation, and immune system processes by altering regional promoter methylation, indicating that these pathways play pivotal roles in the action of hypomethylating agents. OR21 induced cell differentiation via upregulation of the late cell differentiation drivers
    MeSH term(s) Administration, Oral ; Animals ; Antimetabolites, Antineoplastic/pharmacology ; Apoptosis ; Cell Proliferation ; Decitabine/chemistry ; Decitabine/pharmacology ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Macaca fascicularis ; Mice ; Mice, Inbred BALB C ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/metabolism ; Myelodysplastic Syndromes/pathology ; Silanes/chemistry ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
    Chemical Substances Antimetabolites, Antineoplastic ; Silanes ; Decitabine (776B62CQ27)
    Language English
    Publishing date 2021-05-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2063563-1
    ISSN 1538-8514 ; 1535-7163
    ISSN (online) 1538-8514
    ISSN 1535-7163
    DOI 10.1158/1535-7163.MCT-20-1125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top